Edgar B. (Chip) Cale, has served as our General Counsel since September 2019 and Corporate Secretary since December 2019. From June 1998 to July 2019, Mr. Cale served in various senior leadership roles at GlaxoSmithKline plc, a multinational pharmaceutical company, including Senior Vice President, Legal Corporate Functions; Vice President, Associate General Counsel, Legal Operations, WWBD; Vice President, General Counsel, GSK Vaccines; and Assistant General Counsel. Prior to that, Mr. Cale served as a corporate and securities lawyer supporting emerging growth companies in the life science and technology industries at Venture Law Group LLP and Brobeck, Phleger & Harrison LLP. Mr. Cale received a BS in Biology from the University of Pennsylvania and a JD from the University of California, Berkeley.

Robin DeRogatis has served as our Head of Human Resources since May 2020 and brings more than 30 years of broad corporate and consulting experience in Human Resources. Prior to joining Passage Bio, Robin served in various Human Resources leadership roles at several pharmaceutical and biotech companies including: Cephalon, Teva, Johnson & Johnson and Innocoll. Additionally, she spent several years as a strategic Human Resources consultant working with emerging life sciences companies. Robin received an MBA from Rutgers University and BA in mathematics and computer science from Shippensburg University.

Mark Forman has served as our Chief Medical Officer since July 2021. Before joining Passage Bio, he led the ADDF Scientific Affairs team that oversees the drug discovery and drug development portfolio. Dr. Forman is a neuropathologist and neuroscientist who, prior to joining ADDF, was vice president at Acadia Pharmaceuticals, where he was head of translational medicine, responsible for preclinical and early clinical development and contributed to development of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. Dr. Forman also spent 12 years at Merck where he was executive director and neuroscience lead in translational medicine, responsible for the neuroscience portfolio in early clinical development including contributions to the development of more than 20 novel therapeutics and multiple New Drug Applications. Dr. Forman has been a member of scientific advisory board for Biomarkers and Treat FTD at the Association for Frontotemporal Dementia since 2012. Dr. Forman received his PhD at Rockefeller University, MD at Duke University and BS at Yale University.

Alex Fotopoulos, MSc, MBA, has served as our Chief Technical Officer since July 2019. From November 2017 to July 2019, Mr. Fotopoulos served as Senior Vice President, Technical Operations, Gene Therapy of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company. From May 2016 to November 2017, Mr. Fotopoulos served as Senior Vice President, Technical Operations of Dimension Therapeutics, Inc., a biotechnology company, acquired by Ultragenyx Pharmaceutical Inc., focusing on the development of gene therapy for rare diseases associated with the liver and caused by genetic mutations. From August 2011 to May 2016, Mr. Fotopoulos served in various senior leadership roles at Momenta Pharmaceuticals, Inc., a biotechnology company, including Vice President, Technical Operations and Senior Director, Technical Operations. Prior to that, Mr. Fotopoulos served for 18 years in various senior leadership roles at Biogen, Inc., a biotechnology company, including Senior Director, Global Manufacturing Engineering and Director, Global Engineering Technology. Mr. Fotopoulos received a Diploma in Chemical Engineering at the National Technical University of Athens, Greece, an MSc in Chemical Engineering from Tufts University, and an MBA in General Management from the F.W. Olin Graduate School of Business at Babson College.

Bruce A. Goldsmith, PhD, has served as our President and Chief Executive Officer and President and as a member of our board of directors since January 2020. Dr. Goldsmith served as an Advisor and Venture Partner at Deerfield Ventures from January 2019 to January 2020. From April 2019 to January 2020, Dr. Goldsmith also served as Interim Chief Executive Officer of Civetta Therapeutics. Prior to that, Dr. Goldsmith served initially as Chief Business Officer and then as Chief Operating Officer at Lycera Corp. from April 2013 to January 2019. From 2008 to 2012, Dr. Goldsmith served as Vice President and then Senior Vice President of Corporate Development at Allos Therapeutics. Prior to Allos, Dr. Goldsmith served in various leadership roles at GPC Biotech in 2007 and Tibotec Therapeutics, a subsidiary of Johnson & Johnson, from 2005 to 2007. Dr. Goldsmith also previously held various positions at Johnson & Johnson in oncology global strategic marketing, business development and licensing, and acquisition finance. Prior to joining Johnson & Johnson, Dr. Goldsmith was a research fellow at Novartis Pharma K.K., where he conducted scientific research in a neurodegeneration drug discovery group. Dr. Goldsmith received a BA in Biology from Colgate University, a PhD in Biology with a research thesis in neuroscience from the University of Pennsylvania, and an MBA from Columbia University. We believe that Dr. Goldsmith is qualified to serve on our board of directors due to his experience in the biopharmaceutical and biotechnology industry.

Simona King has served as our Chief Financial Officer since August 2021. She has more than 20 years’ strategic finance experience in the pharmaceutical and biotech industry, with both large and small companies. Her experience ranges from counseling executive teams on growth strategies to managing equity and debt financing to launching blockbuster products. She joins Passage Bio from Tmunity Therapeutics, where she served as CFO. Prior to that she was at Emergent BioSolutions as vice president of financial planning, analysis and assistant treasurer. Before Emergent, she worked for 19 years at Bristol Myers Squibb, holding a number of finance roles of increasing responsibility across most functional aspects of the organization, including mergers and acquisitions, R&D, commercial and manufacturing, eventually leading the company’s global financial processes as executive director of corporate financial planning and analysis. Ms. King is a certified public accountant. She earned her BA in economics at Kalamazoo College, and her MBA in finance from Columbia Business School. She also has a diploma in African Studies from the University of Cape Town, where she attended as a Rotary Ambassadorial Scholar.

Jill M. Quigley has served as our Chief Operating Officer since November 2018. From 2017 to 2018, Ms. Quigley served as Chief Executive Officer of Nutrinia Ltd., a pharmaceutical company focused on the treatment of rare conditions of the gastrointestinal tract. From 2012 to 2016, Ms. Quigley served as Senior Counsel of NPS Pharmaceuticals, a biotechnology company focused on developing treatments for rare diseases, which was acquired by Shire plc in March 2015. From 2011 to 2012, Ms. Quigley served as Corporate Counsel for Pharmasset, Inc., a pharmaceutical company. Ms. Quigley began her career as an associate with the law firm of Dechert LLP and later served as Assistant Corporate Counsel for Integra LifeSciences Holdings Corporation. She serves on the Advisory Board for Life Science Cares and Board member for Terns Pharmaceuticals. Ms. Quigley received a BA in Communications, Legal Institutions, Economics & Government (CLEG) from American University and a JD from Rutgers School of Law.

Eliseo Oreste Salinas, MD, MSc, has served as our chief research & development (R&D) officer since March 2021. He joined our company from Acadia Pharmaceuticals, where he was chief scientific officer (CSO), senior vice president and head of External Innovation since September 2018. Dr. Salinas has 30 years of experience developing diverse therapeutic products for central nervous system and other disorders, spanning small molecules, biologics and cell therapy. He has been directly involved with numerous investigational new drug (IND) applications and 15 regulatory approvals. For the last 17 years of his career, Dr. Salinas has managed R&D organizations in mid-size companies, such as Shire and Elan Pharmaceuticals, where he was executive vice president, R&D and CSO, and executive vice president, head of development and chief medical officer, respectively. He also has managed R&D at small pharmaceutical and biotechnology companies, including Adolor, StemCell Inc. and New World Laboratories. Dr. Salinas received his MD from the University of Buenos Aires, Argentina, completed his residency in psychiatry at the Clinique des Maladies Mentales et de l'Encéphale, Paris, and obtained his Master of Science degree in pharmacology from the Université Pierre et Marie Curie, Académie de Paris.

Maria Törnsén has served as our Chief Commercial Officer since July 2021. Prior to joining Passage Bio, Ms. Törnsén, who has nearly 20 years of global commercial experience, was at Sarepta Therapeutics, where she was senior vice president, general manager, US. At Sarepta, she led the launch of the company’s second and third products for Duchenne muscular dystrophy. She also led launch preparations for future gene therapies and double-digit-year-over-year sales growth in 2019 and 2020. Ms. Törnsén joined Sarepta in 2019 from Sanofi Genzyme, where she served as the global therapeutic head for rare neurological, metabolic and endocrine diseases with responsibility for both marketed and pipeline products. Before Sanofi Genzyme, which she joined in 2017, she worked at Shire from 2011 to 2017, beginning in marketing in rare diseases before moving to the neuroscience division. While at Shire, she relocated to the United States and led US sales and marketing for the endocrine franchise. Before joining Shire, Ms. Törnsén was at Merck KGaA from 2006 to 2011 in Switzerland where she held a number of marketing leadership roles in neurology. She began her industry career as a sales representative in 2002 with Eli Lilly in Sweden, launching three products. She received her MS in International Business Administration from Lund University in Sweden.

James M. Wilson, MD, PhD, is the Director of the Gene Therapy Program; Rose H. Weiss Professor and Director of the Orphan Disease Center and Professor of Medicine and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wilson serves as Chief Scientific Advisor at Passage Bio. Dr. Wilson’s laboratory has made seminal contributions to the technology of gene transfer and has paved the way for translation of these technologies into the clinic. He has published over 550 papers and is named on over 110 patents. After launching his faculty career in the Howard Hughes Medical Institute at the University of Michigan, he moved to the University of Pennsylvania in 1993. Dr. Wilson completed his training in Internal Medicine at the Massachusetts General Hospital followed by a postdoctoral fellowship at the Whitehead Institute, where he began his work in gene therapy.

Athena Countouriotis, MD, has served as a member of our board of directors since February 2020. Dr. Countouriotis has also served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018, and from May 2018 to September 2018, she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018, and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a BS from the University of California, Los Angeles, and an MD from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. We believe that Dr. Countouriotis is qualified to serve on our board of directors due to her broad oncology biotech leadership experience and history of guiding multiple development programs to approval.

Bruce A. Goldsmith, PhD, has served as our President and Chief Executive Officer and President and as a member of our board of directors since January 2020. Dr. Goldsmith served as an Advisor and Venture Partner at Deerfield Ventures from January 2019 to January 2020. From April 2019 to January 2020, Dr. Goldsmith also served as Interim Chief Executive Officer of Civetta Therapeutics. Prior to that, Dr. Goldsmith served initially as Chief Business Officer and then as Chief Operating Officer at Lycera, Corp. from April 2013 to January 2019. From 2008 to 2012, Dr. Goldsmith served as Vice President and then Senior Vice President of Corporate Development at Allos Therapeutics. Prior to Allos, Dr. Goldsmith served in various leadership roles at GPC Biotech in 2007 and Tibotec Therapeutics, a subsidiary of Johnson & Johnson, from 2005 to 2007. Dr. Goldsmith also previously held various positions at Johnson & Johnson in oncology global strategic marketing, business development and licensing and acquisition finance. Prior to joining Johnson & Johnson, Dr. Goldsmith was a research fellow at Novartis Pharma, K.K., where he conducted scientific research in a neurodegeneration drug discovery group. Dr. Goldsmith received a BA in Biology from Colgate University, a PhD in Biology with a research thesis in neuroscience from the University of Pennsylvania, and an MBA from Columbia University. We believe that Dr. Goldsmith is qualified to serve on our board of directors due to his experience in the biopharmaceutical and biotechnology industry.

Maxine Gowen, Ph.D., has served as a member of Passage Bio’s board of directors since Feb. 2021 and was appointed chairwoman in August 2021. Dr. Gowen is chief executive officer of Tamuro Bio, a role that she has held since July 2019. Prior to Tamuro Bio, she was the founding president and chief executive officer of Trevena, Inc. from 2007 to October 2018. Previously she held a variety of leadership roles at GlaxoSmithKline, GSK, over a period of 15 years. As senior vice president for GSK’s Center of Excellence for Drug Discovery, she developed an innovative new approach to externalizing drug discovery. She also currently serves on the boards of directors for Aclaris Therapeutics, Inc., Idera Pharmaceuticals, Inc., Merus N.V., and the private company Tamuro Bio. Dr. Gowen graduated with a BSc in biochemistry from the University of Bristol, UK, received a PhD in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. We believe Dr. Gowen is qualified to serve as chairwoman of our board of directors due to her deep biopharmaceutical industry experience in research and development, as a board member and CEO.

Saqib Islam has served as a member of our board of directors since March 2019. Mr. Islam has also served as Chief Executive Officer and a member of the board of directors of SpringWorks Therapeutics, Inc., a biopharmaceutical company, since August 2018, and from August 2017 to August 2018, he served as Chief Financial Officer and Chief Business Officer of SpringWorks. From February 2016 to August 2017, Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc., a biotechnology company. From February 2013 to February 2016, Mr. Islam served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc., a pharmaceutical company. Prior to joining Alexion, Mr. Islam worked for more than 25 years in international business management with a focus on business development, strategic decision-making and planning and capital markets, previously holding managing director positions at Morgan Stanley and Credit Suisse. Mr. Islam received a BA in Commerce from McGill University and a JD from Columbia Law School. We believe that Mr. Islam is qualified to serve on our board of directors due to his experience and expertise in operations management and executive leadership at various biopharmaceutical and biotechnology companies.

Sandip Kapadia has served as member of our board of directors since December 2019. Mr. Kapadia brings over 25 years of science industry experience and has served as the Chief Financial Officer (CFO) for Harmony Biosciences since March 2021. Previously Mr. Kapadia was CFO for Intercept Pharmaceuticals. Before Intercept, Mr. Kapadia served in various leadership capacities within finance for more than 19 years at Novartis International AG and Novartis affiliates in the United Kingdom, Netherlands, Switzerland and the US. Mr. Kapadia received a BS in Accounting from Montclair State University and an MBA from Rutgers University, and is also a US Certified Public Accountant. Mr. Kapadia currently serves on the boards of directors of Molecular Partners AG and VectivBio Holding AG. We believe that Mr. Kapadia is qualified to serve on our board of directors due to his leadership experience in the biopharmaceutical industry and finance expertise.

Derrell D. Porter, MD, has served as a member of Passage Bio’s board of directors since May 2021. Dr. Porter is founder and chief executive officer of Cellevolve Bio, Inc. Prior to founding and leading Cellevolve Bio in 2020, Dr. Porter served as senior vice president and head of Commercial at Atara Biotherapeutics, Inc. from May 2017 to October 2019. While there, he built the global commercial organization, including its product launch strategy. Prior to joining Atara, Dr. Porter served as a vice president with Gilead Sciences from April 2013 to May 2017, where he was responsible for corporate strategy, commercial planning, and global launch preparation for all of Gilead’s therapeutic areas. Previously, Dr. Porter was at AbbVie and Amgen, where he served in multiple US, EU and global roles of increasing responsibility in strategy, corporate development, business unit management, and sales and marketing. Dr. Porter began his career at McKinsey & Company in Los Angeles as part of the West Coast Health Care Practice. He currently serves on the boards of directors of several private companies. Dr. Porter holds an MD and an MBA from the University of Pennsylvania, and a bachelor’s degree in psychobiology / neuroscience from the University of California, Los Angeles. We believe Dr. Porter is qualified to serve on our board of directors due to his strong corporate strategy, product development and commercial experience.

Liam Ratcliffe, MD, PhD, has served as a member of our board of directors since September 2019. Dr. Ratcliffe has also served as the Head of Biotechnology at Access Industries since April 2019. From September 2008 to April 2019, Dr. Ratcliffe served as Managing Director at New Leaf Venture Partners, a healthcare venture capital firm, where he focused on investing in therapeutics and therapeutic platform companies. Prior to joining New Leaf, Dr. Ratcliffe held various positions of increasing responsibility at Pfizer Inc., a multinational pharmaceutical corporation, including Senior Vice President and Development Head for Neuroscience, and Worldwide Head of Clinical Research and Development. Dr. Ratcliffe currently serves on the board of directors of Arvinas, Inc. Dr. Ratcliffe previously served on the boards of directors of Unum Therapeutics, Inc., Edge Therapeutics, Inc., Array Biopharmaceuticals, Inc., Deciphera Pharmaceuticals, Inc. and Aptinyx Inc. Dr. Ratcliffe received an MBA from the University of Michigan and an MD and PhD in Immunology from the University of Cape Town, and he completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa. We believe that Dr. Ratcliffe is qualified to serve on our board of directors due to his extensive experience in the venture capital industry, medical and scientific background and training, and leadership at various biopharmaceutical and biotechnology companies.

Thomas Woiwode, PhD, has served as a member of our board of directors since September 2018. Since 2002, Dr. Woiwode has served in various investment and operational roles at Versant Venture Management, LLC, a healthcare investment firm, including Managing Director since July 2014 and a Venture Partner from 2011 to 2014. From 2011 to 2013, Dr. Woiwode served as Chief Operating Officer of Okarios AG, a biopharmaceutical company. Previously, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Venture Management, LLC, and in this role, served as the founding Chief Business Officer for three biotechnology portfolio companies. Prior to Versant, Dr. Woiwode served as a Research Scientist at XenoPort, Inc., a biotechnology company. Dr. Woiwode currently serves on the boards of directors of Gritstone Oncology, Inc. and Adverum Biotechnologies, Inc., as well as several private companies. Dr. Woiwode previously served on the board of directors of Audentes Therapeutics, Inc. and Crispr Therapeutics AG, both public biotechnology companies. Dr. Woiwode received a BA in English and a BS in Chemistry from the University of California, Berkeley and a PhD in Organic Chemistry as an NSF Fellow from Stanford University. We believe that Dr. Woiwode is qualified to serve on our board of directors due to his educational background, experience as a board member and senior executive of biotechnology and pharmaceutical companies, and experience as an investor in new life sciences companies.